TWi Biotechnology, Inc. Announces First Patient Enrolled in Phase 2/3 Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc. (6610 TWO), a clinical stage biotechnology company specializing in the development of repositioned drugs for unmet medical needs, announced that on April 4, 2024, the first patient was dosed in its phase 2/3 trial of AC-203 for the treatment of generalized epidermolysis bullosa simplex (EBS) at Premier Specialists Pty Ltd in Australia. 2023-06-06TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments 2021-06-28Inmagene and TWIB Partner to Develop AC-1101 for Multiple Dermatological Immunological Diseases
Inmagene and TWIB Partner to Develop AC-1101 for Multiple Dermatological Immunological Diseases 2021-01-07【PR Newswire】Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203
Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases. 2020-05-07TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA
The AC-1101 Phase 1 trial is an open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 from repeated topical applications of AC-1101 gel to single oral administration of its oral reference product in healthy adult volunteers in Canada and is expected to be completed at the end of 2020. 2019-01-23TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of- Concept Study of AC-203 for Treatment of Epidermolysis Bullosa
TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of- Concept Study of AC-203 for Treatment of Epidermolysis Bullosa 2018-11-15TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy 2018-10-20TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa
TWi Biotechnology, Inc. Announced the initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa 2018-02-07TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa
TWi Biotechnology, Inc. Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa 2017-11-01TWi Biotechnology Inc. Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting
TWi Biotechnology Inc. Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting